Riskpilot← Back to searchSign inGet full accessONEMED AS
ASActiveOrg 953424894Bølerveien 63, 2020 SkedsmokorsetWholesale of pharmaceutical and medical goods · NACE 4646Est. 198945 employeeswww.onemed.no
Revenue 2024
NOK 491,9M
+26% vs 2023
EBITDA margin
5.3%
+222% vs 2023
Equity ratio
17.7%
Financial strength
Net profit 2024
NOK 7,8M
-12% vs 2023
| Revenue | NOK 491,9M | +26% |
| EBITDA | NOK 26,3M | +222% |
| Net profit | NOK 7,8M | -12% |
| Total assets | NOK 402,6M | +23% |
| Equity | NOK 71,1M | +12% |
| Employees | 45 | — |
Legal name
ONEMED AS
Org number
953424894
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. september 1989
Share capital
NOK 13 090 000
Employees
45 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Kjøp og salg av sykepleieprodukter, handel, produksjon og agenturvirksomhet, konsulentvirksomhet, generell helsebistand, og hva hermed står i forbindelse, herunder å delta i andre selskaper med lignende virksomhet.
Address
Bølerveien 63, 2020 Skedsmokorset
Phone
+4740002136
Email
bestilling.no@onemed.com
Website
www.onemed.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103 593 | 101 833 | 55 589 | 51 140 | 57 555 | 57 779 | 63 553 | 68 756 | 99 745 | 160 649 | 179 490 | 227 927 | 519 666 | 746 532 | 443 239 | 389 678 | 491 871 |
| Staff expenses | −19 099 | −17 566 | −10 125 | −9 717 | −8 541 | −10 574 | −9 672 | −10 364 | −14 551 | −19 338 | −22 851 | −25 990 | −32 812 | −39 392 | −31 892 | −38 079 | −49 921 |
| EBITDA | 1 973 | 471 | −4 933 | −5 734 | −5 585 | −3 235 | 3 012 | −9 605 | −8 577 | −11 260 | −6 610 | −2 494 | 10 938 | 8 625 | 26 086 | 8 156 | 26 298 |
| Depreciation & amort. | −3 295 | −3 115 | −2 475 | −834 | −83 | −78 | −85 | −85 | −49 | −125 | −237 | −306 | −496 | −1 537 | −1 649 | −1 733 | −1 005 |
| EBIT | −1 322 | −2 644 | −7 408 | −6 567 | −5 667 | −3 314 | 2 928 | −9 690 | −8 625 | −11 385 | −6 846 | −2 799 | 10 441 | 7 087 | 24 438 | 6 423 | 25 292 |
| Net financials | −1 057 | −974 | −961 | −716 | −177 | −347 | 710 | 4 324 | 1 584 | 2 171 | 1 752 | 3 205 | 6 463 | 4 028 | 5 675 | 4 991 | −15 309 |
| Profit before tax | −2 379 | −3 618 | −8 368 | −7 283 | −5 844 | −3 660 | 3 637 | −5 366 | −7 042 | −9 214 | −5 095 | 405 | 16 904 | 11 116 | 30 113 | 11 415 | 9 983 |
| Tax | −647 | −998 | −0 | −0 | 9 811 | −0 | −0 | −0 | −16 513 | −1 431 | −341 | 98 | 3 720 | 3 223 | 6 712 | 2 548 | 2 224 |
| Net profit | −1 732 | −2 620 | −8 368 | −7 283 | −15 654 | −3 660 | 3 637 | −5 366 | 9 471 | −7 783 | −4 754 | 307 | 13 184 | 7 893 | 23 400 | 8 867 | 7 759 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 47 160 | 37 496 | 37 351 | 38 828 | 23 213 | 19 350 | 21 592 | 28 330 | 41 875 | 48 474 | 51 216 | 69 978 | 127 049 | 255 879 | 140 250 | 328 227 | 402 608 |
| Equity | 16 813 | 14 193 | 5 825 | 28 542 | 12 887 | 9 227 | 12 864 | 7 498 | 16 969 | 9 430 | 4 677 | 9 984 | 23 168 | 31 061 | 54 461 | 63 328 | 71 086 |
| Long-term debt | 13 000 | 11 187 | 25 000 | 2 000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85 949 | 0 | 123 237 | 123 165 |
| Short-term debt | 16 988 | 12 116 | 6 526 | 8 286 | 10 326 | 10 124 | 8 728 | 20 832 | 24 906 | 39 044 | 46 539 | 59 994 | 103 880 | 138 869 | 85 789 | 141 662 | 208 356 |
| Total debt | 29 988 | 23 303 | 31 526 | 10 286 | 10 326 | 10 124 | 8 728 | 20 832 | 24 906 | 39 044 | 46 539 | 59 994 | 103 880 | 224 818 | 85 789 | 264 899 | 331 521 |
EBITDA margin
5.3%
This company
15.8%
Market median
-66% vs market
20082024
Equity ratio
17.7%
This company
38.2%
Market median
-54% vs market
20082024
Return on equity
10.9%
This company
18.4%
Market median
+41% vs market
20082024
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20082024
Asset turnover
1.22×
This company
1.12×
Market median
+9% vs market
20082024
Debt / equity
4.66×
This company
0.62×
Market median
-652% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JK Chief Executive Officer | Chief Executive Officer | 2008 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Tamro Medlab Oy | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ONEMED AS 
ADCARE ASBoard members of ONEMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Knoph | Chief Executive Officer | 0 companies |
| Carl Johan Falk | Chairman | 0 companies |
| Thomas Philip Moss | Board of Directors | 0 companies |
| Lars Peter Nilsson | Chairman | 0 companies |
| Jens Ole Ørneberg | Board of Directors | 0 companies |
| Cecilie Louise Buøen | Board of Directors | 0 companies |